Bio-Rad launches its flagship project, the BioPlex 2200, and Bio-Rad Israel was chosen to be the product's main software developer
The science service
The Bio-Rad company is currently distributing a new product called BioPlex2200. This is a unique and automatic platform that allows a collection of tests to be performed simultaneously on one blood sample. The first menu, ANA, includes 13 tests to identify a variety of autoimmune diseases. Autoimmune diseases are characterized by the problematic phenomenon that the antibody system designed to protect the body, attacks it.
The symptoms of the diseases are many and varied, which makes the identification process a challenge. Product development includes hardware, software and chemistry development. The software that is the "glue" among the other components was developed in Israel, by the local branch of the B-Rad global company.
Bio-Rad Israel has been the main software development center of the parent company for many years and was chosen as a partner in this project, the flagship project of the parent company, following many successes in complex projects in the company. Bio-Rad Israel was created 15 years ago as a result of the acquisition of the Israeli company Braspek by Bio-Rad Labortoris in 1991. It works to develop software for a wide range of medical and clinical diagnostic products for the global company in addition to selling all of the parent company's products in Israel. Bio-Rad Israel is Bio-Rad's main software development center in the world, and it leads the technological advancement and innovation of the company. The company is headed by Liat Zelig, who has accompanied the company since the day of its purchase.
Biotechnology expert in Israel
Drafting and editing: H. J. Glykasm, translations and technical writing
